Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care

European Psychiatry

Volumn 23, Issue 8, 2008, Pages 561-566

  Kolotkin, Ronette L ^a,b   Corey Lisle, Patricia K ^c   Crosby, Ross D ^d,e   Kan, Hong J ^c   McQuade, Robert D ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Life Consulting   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^e UND School of Medicine & Health Sciences Southeast Campus   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotics; Obesity; Quality of life; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SELF ESTEEM; SEXUAL BEHAVIOR; SIDE EFFECT; STANDARD; TREATMENT DURATION; WEIGHT CHANGE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPERAZINES; QUALITY OF LIFE; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF CONCEPT; SOCIAL ADJUSTMENT;

EID: 56249147209     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.01.1421     Document Type: Article

References (33)

1. Allison D.B., Mackell J.A., and McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54 4 (2003) 565-567
2. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 2 (2004) 596-601
3. Angermeyer M.C., and Matschinger H. Neuroleptics and quality of life. A patient survey. Psychiatr Prax 27 2 (2000) 64-68
4. Brixner D.I., Said Q., Corey-Lisle P.K., Tuomari A.V., L'Italien G.J., Stockdale W., et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 40 4 (2006) 626-632
5. Catapano L., and Castle D. Obesity in schizophrenia: what can be done about it?. Australas Psychiatry 12 1 (2004) 23-25
6. Crosby R.D., Kolotkin R.L., and Williams G.R. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 57 11 (2004) 1153-1160
7. Dubisar B.M., Stoner S.C., Reynolds J., Khan R., and Ramlatchman L. Adverse effects of atypical antipsychotic agents and their effects on quality of life. Pharmacotherapy 24 7 (2004) 843-847
8. Engel S.G., Crosby R.D., Kolotkin R.L., Hartley G.G., Williams G.R., Wonderlich S.A., et al. The impact of weight loss and regain on obesity-specific quality of life: mirror image or differential effect. Obes Res 11 (2003) 1207-1213
9. Fakhoury W.K., Wright D., and Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 16 3 (2001) 153-162
10. FDA. Guidance for the clinical evaluation of weight-control drugs (1996). http://wwwfdagov/cder/guidance/obesitypdf
11. Gadbury G.L., Coffey C.S., and Allison D.B. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 4 3 (2003) 175-184
12. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 29 4 (2006) 303-319
13. Homel P., Casey D., and Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 55 3 (2002) 277-284
14. Jia H., and Lubetkin E.I. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 27 2 (2005) 156-164
15. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry 22 7 (2007 Oct) 433-443 [Epub 2007 Jun 7]
16. Kolotkin R.L., and Crosby R.D. Psychometric evaluation of the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite) in a community sample. Qual Life Res 11 2 (2002) 157-171
17. Kolotkin R., Crosby R., Corey-Lisle P., Li H., and Swanson J. Performance of a weight-related measure of quality of life in a psychiatric sample. Qual Life Res 15 4 (2006) 587-596
18. Kolotkin R.L., Crosby R.D., Kosloski K.D., and Williams G.R. Development of a brief measure to assess quality of life in obesity. Obes Res 9 (2001) 102-111
19. Kolotkin R.L., Crosby R.D., Williams G.R., Hartley G.G., and Nicol S. The relationship between health-related quality of life and weight loss. Obes Res 9 (2001) 564-571
20. Kolotkin R.L., Meter K., and Williams G.R. Quality of life and obesity. Obes Rev 2 (2001) 219-229
21. Lieberman J.A. Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 63 10 (2006) 1069-1072 10.1001/archpsyc.63.10.1069
22. McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 Suppl 18 (2004) 47-56
23. Muller D.J., Muglia P., Fortune T., and Kennedy J.L. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 49 4 (2004) 309-329
24. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 Suppl 1 (2003) 83-96
25. Sach T.H., Barton G.R., Doherty M., Muir K.R., Jenkinson C., and Avery A.J. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond) 31 (2007) 189-196
26. Schwartz T.L., Nihalani N., Jindal S., Virk S., and Jones N. Psychiatric medication-induced obesity: a review. Obes Rev 5 2 (2004) 115-121
27. Strassnig M., Brar J.S., and Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res 62 1-2 (2003) 73-76
28. Susce M.T., Villanueva N., Diaz F.J., and de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66 2 (2005) 167-173
29. Tardieu S., Micallef J., Gentile S., and Blin O. Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 4 3 (2003) 129-138
30. Toalson P., Ahmed S., Hardy T., and Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 6 4 (2004) 152-158
31. Uzun S., Kozumplik O., Mimica N., and Folnegovic-Smalc V. Aripiprazole: an overview of a novel antipsychotic. Psychiatr Danub 17 1-2 (2005) 67-75
32. Virk S., Schwartz T.L., Jindal S., Nihalani N., and Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev 5 3 (2004) 167-170
33. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66 1 (2004) 51-57